Martindale Pharma improves Aurum pre-filled syringe packaging

Published: 9-Nov-2011
Packaging Regulatory

To ensure ease of use and improve patient safety

Martindale Pharma, a UK manufacturer and supplier of pharmaceutical specials, has made a number of improvements to its Aurum range of 11 pre-filled syringes.

The Aurum syringes are used for on-the-spot administration of drugs where high visibility and simple drug identification is crucial.

The Brentwood, Essex-based firm has redesigned the range to enhance ease of use and help improve patient safety. Specific improvements include new colour-differentiated packaging; colour-differentiated translucent boxes that confirm contents; and colour-differentiated labels. In addition the firm has improved tamper-evident labels and the packaging is latex-free and Luer Lock fitting.

The firm says its new colour-differentiated packaging meets national and international colour differentiation standards on syringe labelling and also the Royal College of Anaesthetists recommendations on syringe labelling in critical care.

See more

You may also like

Packaging

Parenteral Drug Association to host innovation in sustainable packaging workshop at Pharmapack 2026

Read more
The Parenteral Drug Association (PDA) will host a half-day workshop titled “PDA Innovation in Sustainable Packaging Workshop 2026” on Day One of Pharmapack Europe in Paris

Trending Articles

  1. Shilpa Medicare targets US approval for extended-release Ondansetron injection for CINV Shilpa Medicare plans to pursue US approval and licensing partners for OERIS after a Phase III study in India met all primary and secondary endpoints and showed a strong safety profile in chemotherapy-induced nausea and vomiting
  2. 3PBIOVIAN secures French CIR certification for Spain and Finland R&D sites The CDMO has obtained French Crédit d’Impôt Recherche (CIR) certification for its Pamplona and Turku sites, enabling French partners to access tax incentives when collaborating on recombinant protein and advanced therapy projects
  3. MedPharm completes FDA inspection of manufacturing plant in Durham The topical drug product manufacturing facility in North Carolina successfully completed its FDA inspection for the commercial manufacture of drug products with no Form 483 issued plus an NAI classification
  4. Novo Nordisk wins positive ruling for semaglutide compound patent from China’s Supreme People’s Court The company has welcomed a decision by China’s Supreme People’s Court affirming the validity of its semaglutide compound patent, strengthening confidence for foreign drugmakers operating in the Chinese market
  5. New thermal inkjet printer expands AM Labels’ coding portfolio M2 system delivers high resolution variable data printing at production-line speeds

Upcoming event

Pharmapack

21–22 January 2026 | Exhibition | Paris, France See all

You may also like

Packaging

Parenteral Drug Association to host innovation in sustainable packaging workshop at Pharmapack 2026

The Parenteral Drug Association (PDA) will host a half-day workshop titled “PDA Innovation in Sustainable Packaging Workshop 2026” on Day One of Pharmapack Europe in Paris
Packaging

ACG Packaging Materials launches SuperPod to set a new benchmark for cold-form blister design

ACG Packaging Materials, which manufactures the world’s widest range of film and foil blister and lidding products, has launched its breakthrough cold-form blister technology: SuperPod
Packaging

Vetter reaches key launch milestones for the V-OVS next tamper-evident syringe closure system

Several recent steps move the closure toward commercialisation
Regulatory

3PBIOVIAN secures French CIR certification for Spain and Finland R&D sites

The CDMO has obtained French Crédit d’Impôt Recherche (CIR) certification for its Pamplona and Turku sites, enabling French partners to access tax incentives when collaborating on recombinant protein and advanced therapy projects
Regulatory

Shilpa Medicare targets US approval for extended-release Ondansetron injection for CINV

Shilpa Medicare plans to pursue US approval and licensing partners for OERIS after a Phase III study in India met all primary and secondary endpoints and showed a strong safety profile in chemotherapy-induced nausea and vomiting
Manufacturing

MedPharm completes FDA inspection of manufacturing plant in Durham

The topical drug product manufacturing facility in North Carolina successfully completed its FDA inspection for the commercial manufacture of drug products with no Form 483 issued plus an NAI classification
Manufacturing

New thermal inkjet printer expands AM Labels’ coding portfolio

M2 system delivers high resolution variable data printing at production-line speeds
Subscribe now